- Home
- DCI vs LEGN Comparison
DCI vs LEGN Comparison
Compare DCI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCI | LEGN |
|---|---|---|
| Founded | 1915 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 5.9B |
| IPO Year | 1987 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DCI | LEGN |
|---|---|---|
| Price | $92.26 | $22.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $92.50 | $69.67 |
| AVG Volume (30 Days) | 750.4K | ★ 2.5M |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.21 | N/A |
| Revenue | ★ $3,726,200,000.00 | $909,045,000.00 |
| Revenue This Year | $4.39 | $68.83 |
| Revenue Next Year | $4.49 | $51.27 |
| P/E Ratio | $28.78 | ★ N/A |
| Revenue Growth | 2.37 | ★ 74.75 |
| 52 Week Low | $57.45 | $22.28 |
| 52 Week High | $95.00 | $45.30 |
Technical Indicators
Market Signals| Indicator | DCI | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.65 | 21.96 |
| Support Level | $90.08 | $26.43 |
| Resistance Level | $95.00 | $28.97 |
| Average True Range (ATR) | 1.92 | 1.57 |
| MACD | 0.17 | -0.43 |
| Stochastic Oscillator | 66.71 | 0.91 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.